Recent Advances in the Management of Rheumatoid Arthritis: A Closer Look at Emerging Therapies

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2016 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 15, 2017 to January 31, 2018

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Lilly USA, LLC

Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body's own tissues which typically result in warm, swollen, and painful joints. Additionally, systemic complications and comorbid conditions make the disease difficult to manage. There is no cure for RA thus treatment focuses on managing the disease and controlling symptoms. Fortunately, several new medications have become available as many patients have an inadequate response or can become intolerant to the widely used anti-TNF therapies. Clinicians have recently been equipped with more treatment options, including janus kinase (JAK) inhibitors which are changing the way RA patients are treated.

Upon Completion of this activity, participants will be able to:

  • Analyze the efficacy and safety of new and emerging therapies in the management of Rheumatoid Arthritis (RA) for achieving treatment goals

  • Discuss how mechanisms of action of emerging agents target underlying pathophysiology for RA, with an emphasis on the janus kinase pathway

  • Examine recent clinical trial data of emerging JAK inhibitors in patients with rheumatoid arthritis

  • Tailor treatment regimens for moderate-to-severely active RA based on repeated assessment of disease activity, functional status, treatment response, and other patient-specific risks

  • Identify strategies to monitor and manage adverse events associated with emerging RA therapies in order to improve patient adherence

Faculty: Gary M. Owens, MD
Gary Owens Associates


Dr. Owens serves as a consultant AbbVie, Biogen, Novartis and Roche. His presentation has been peer reviewed for bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This activity is supported by an educational grant from
Lilly USA, LLC

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue